Kymera Therapeutics, Inc. (KYMR) Business Profile

What it does

Kymera Therapeutics is a clinical-stage biotechnology company developing oral medicines, primarily for immune and inflammatory diseases. It has no products on the market and has not generated revenue from product sales. Its headquarters are in Watertown, and founder Nello Mainolfi is its chief executive officer.

Kymera’s central approach is targeted protein degradation. Rather than only blocking a protein’s activity, its small-molecule candidates are designed to engage the body’s cellular recycling system to remove disease-causing proteins. The company aims to reach targets that existing technologies have not addressed adequately, including proteins involved in inflammation.

Its lead program, KT-621, targets a protein called STAT6. Kymera is testing it in people with moderate to severe atopic dermatitis, an inflammatory skin disease, and asthma. Its KT-579 program targets IRF5, a regulator of immune responses, and the company plans to test it in people with lupus. Both candidates are intended to be taken orally.

Kymera also develops medicines with partners. Sanofi is advancing KT-485, which targets IRAK4 in inflammatory diseases. Gilead Sciences is advancing KT-200, a molecular glue degrader targeting CDK2 for potential cancer treatment. Kymera expects to advance at least one new molecular entity into clinical testing annually.

How it makes money

Kymera has not generated product-sales revenue. Its revenue has come from research collaboration arrangements with pharmaceutical companies, and it expects collaboration agreements to remain its primary revenue source for the next several years. It has not received royalties under its collaboration agreements. The company must complete clinical development and obtain marketing approval before it can generate revenue from selling its drug candidates.

Under its Sanofi agreement, Kymera is responsible for discovery and preclinical research and specified early clinical work. Sanofi assumes development, manufacturing and commercialization responsibilities after a specified development milestone. The agreement includes potential development and commercial milestone payments and tiered royalties on net sales. Kymera also has an option, on a target-by-target basis, to fund half of U.S. development costs and share equally in U.S. commercialization profits and losses.

Kymera leads research on the CDK2 program partnered with Gilead. Gilead has exercised its option and is advancing KT-200 toward clinical testing. The arrangement can provide payments as the program progresses; future product revenue would depend on successful development and commercialization.

In the second quarter of 2026, collaboration revenue was $65 million, including a $45 million Gilead option exercise fee and a $20 million Sanofi milestone payment. Kymera recognized no collaboration revenue in the third quarter and did not expect additional collaboration revenue for the remainder of 2026.

Collaboration payments depend on agreement terms and development events rather than recurring medicine sales. Kymera expects to finance operations through sources that may include equity, debt and additional collaborations until it can generate significant product revenue, if ever.

Customers and how it sells

Kymera’s current revenue relationships are with collaboration partners rather than buyers of approved Kymera medicines. Sanofi and Gilead are its current development partners, and its past collaboration revenue also included work with Vertex. The Vertex agreement expired after its initial research term.

For its own clinical programs, Kymera is developing potential treatments for patients with immune and inflammatory diseases. KT-621 is being studied in moderate to severe atopic dermatitis and asthma; KT-579 is intended for development in lupus and potentially other autoimmune diseases. If approved, the medicines would need acceptance from patients, medical professionals and third-party payors, as well as healthcare coverage and reimbursement.

Kymera focuses its estimates of the opportunity on the United States, Europe and Japan. The company believes more than 160 million people in those regions have been diagnosed with prevalent immune-inflammatory diseases that its programs could potentially address. Kymera also cites published estimates of approximately 6 to 9 million people in the U.S. aged 12 and up with moderate to severe atopic dermatitis. Its market research found that some patients and prescribers consider injections or boxed warnings barriers to advanced therapies.

Suppliers and costs

Kymera’s spending supports drug discovery, preclinical studies, clinical trials and the development of its research platform. Its discovery capabilities include screening technologies, machine learning, chemistry, proteomics and work with patient disease samples. The company also expects to spend on facilities, staff and protection of its intellectual property.

Kymera contracts to manufacture its drug candidates and must arrange clinical supply and, if products are approved, commercial manufacturing. It works alongside vendors, contract research organizations and contract manufacturers in navigating regulatory requirements. Under the Sanofi agreement, Kymera generally bears the costs of specified discovery, preclinical and early clinical work; Sanofi takes responsibility for development and manufacturing after a specified milestone.

Research and development expenses were $128.5 million in the third quarter of 2026. Kymera expects expenses to increase as it advances development, including preparing for potential Phase 3 studies. If it obtains approvals, it also expects commercialization costs for manufacturing, marketing, sales and distribution.

Competitive position

Kymera competes with companies developing protein degraders and with companies pursuing the same diseases through other approaches, including small molecules and antibodies. It names Arvinas, C4 Therapeutics, Nurix Therapeutics and Foghorn Therapeutics as companies developing small-molecule protein degrader therapies.

In STAT6, Kymera identifies Gilead Sciences, Johnson & Johnson, Pfizer and Sanofi as companies with internal programs or partnerships. Pfizer has a STAT6 program in Phase II. Sanofi is both a collaborator on Kymera’s IRAK4 program and a participant in STAT6 development. Kymera’s potential medicines would also compete against established treatments, including the injectable antibody dupilumab, in the diseases it targets.

Kymera has developed a patent estate and discovery capabilities that include screening, protein analysis and drug optimization. It also has clinical experience across several degrader programs. The company is withholding some KT-579 biomarker dose-response information to protect its competitive position.

Our reading: The patent estate and proprietary know-how could help protect Kymera’s candidates, but the available evidence does not establish how broadly those protections exclude rivals. Our reading: Its experience in moving degraders into clinical testing is a potential advantage, but competing STAT6 and protein-degrader programs limit the strength of that advantage.

Growth opportunities

Kymera’s growth plans depend on advancing its own drug candidates and partnered programs through clinical development, then obtaining approvals and commercializing successful medicines. It intends to expand its pipeline and build development and eventual commercial capabilities, while continuing to consider collaborations.

For KT-621, Kymera completed the placebo-controlled portion of its Phase 2b atopic dermatitis study and expects data by year-end 2026. It plans to begin a Phase 3 atopic dermatitis study by mid-2027, subject to supportive results and alignment with the FDA. Its Phase 2b asthma study is ongoing, with results expected in late 2027. Kymera is also studying whether the STAT6 program could address other Type 2 inflammatory diseases.

For KT-579, the company plans a Phase 1b lupus trial after reporting that the drug degraded IRF5 and affected disease-relevant biomarkers in healthy volunteers. Sanofi is advancing KT-485 in a Phase 1 study, while Gilead is preparing KT-200 for an investigational new drug application planned for 2027.

Kymera estimates that more than 140 million people in the U.S., Europe and Japan have diseases predominantly driven by Type 2 inflammation, including about 48 million with moderate to severe disease. The company believes an effective oral medicine could reach patients who are untreated or poorly served by existing options. These development plans and potential markets do not constitute product sales.

Structural risks

• Clinical development: Kymera’s STAT6 and IRF5 programs are in early clinical development, with other programs still preclinical. Studies may fail to establish the safety or effectiveness needed for approval, or regulators may disagree with their design or results.

• Funding: Kymera will need substantial additional funding. If it cannot raise capital or enter into suitable arrangements when needed, it may have to delay, reduce or eliminate development or commercialization of candidates.

• Regulatory approval and commercialization: Kymera cannot generate product-sales revenue until it successfully completes clinical development and obtains marketing approval. Even if a candidate is approved, it must gain acceptance from patients, medical professionals and payors and obtain adequate coverage and reimbursement.

• Competition and intellectual property: Kymera faces competition from other degraders and established treatment types. It must maintain and defend patent and trade-secret protection, and demonstrate that its candidates compare favorably with existing therapies.

• Partners and supply: Development and potential payments depend in part on the success and terms of collaborations. Kymera also needs manufacturing arrangements for clinical supply and any commercial production.

Bottom line

Our reading

Our reading: Kymera is a drug-development business whose present revenue comes from collaborations, while its longer-term business depends on turning experimental medicines into approved products. Its protein-degradation platform and partnerships support several development paths, but clinical results, regulatory decisions and access to funding remain central uncertainties. The advance of KT-621 and KT-579 provides near-term tests of that approach.